NASDAQ · ALNY
Alnylam Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for ALNY has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $1.46 | $1.73 | $0.94 | 9 |
| Dec 2026 | $1.80 | $2.31 | $1.10 | 8 |
| Mar 2027 | $2.01 | $2.51 | $1.51 | 2 |
| Jun 2027 | $2.57 | $2.91 | $2.23 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · BNK Invest · Zacks · MarketBeat- RTTNews · 6 h agoAlnylam Reports 17% Q3 Revenue Growth, Expands Nucresiran Trial And Advances RNAi Pipeline(RTTNews) – Alnylam Pharmaceuticals, Inc. (ALNY) reported its third-quarter 2026 earnings and revenue, supported by continued growth in its transthyretin (TTR) franchise, particularly AMVUTTRA.
- BNK Invest · 7 h agoNasdaq 100 Movers: FTNT, HONIVIn early trading on Thursday, shares of Honeywell International topped the list of the day's best performing components of the Nasdaq 100 index, trading up 7.5%. Year to date, Honeywell International registers a 42.2% gain. And the worst performing Nasdaq 100 component thus fa
- Zacks · 8 h agoAlnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top EstimatesAlnylam (ALNY) delivered earnings and revenue surprises of +642.47% and +0.63%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · 9 h agoCompared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key MetricsWhile the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- RTTNews · 9 h agoAlnylam Pharmaceuticals Inc. Reports Advance In Q3 Bottom Line(RTTNews) – Alnylam Pharmaceuticals Inc. (ALNY) revealed earnings for its third quarter that Increases, from the same period last year
- RTTNews · 10 h agoAlnylam Pharmaceuticals Q3 26 Earnings Conference Call At 8:30 AM ET(RTTNews) – Alnylam Pharmaceuticals Inc. (ALNY) will host a conference call at 8:30 AM ET on October 29, 2026, to discuss Q3 26 earnings results.
- Zacks · Oct 28, 8:15 AM EDTAlnylam (ALNY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance MeasuresGet a deeper insight into the potential performance of Alnylam (ALNY) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
- MarketBeat · Oct 26, 1:03 PM EDTAlnylam Reports Up to 83% Huntingtin Reduction, Eyes 2027 Pivotal TrialThe Phase 3 Failure That Sent Biotech Winners and Losers in Opposite DirectionsAlnylam Pharmaceuticals (NASDAQ:ALNY) outlined early clinical data for brezosiran, an investigational RNA interference therapy for Huntington’s disease, reporting dose-dependent reductions in cerebrosp
- Zacks · Oct 26, 9:00 AM EDTAnalysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out forKrystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Oct 23, 6:12 AM EDTAlnylam's Brezosiran Lowers Mutant Huntingtin In Phase 1b Huntington's Trial(RTTNews) – Alnylam Pharmaceuticals, Inc. (ALNY) on Friday reported its investigational drug Brezosiran, previously known as ALN-HTT02, reduced mutant huntingtin protein levels in initial Phase 1b trial in Huntington's disease.
- RTTNews · Oct 23, 4:53 AM EDTAlnylam Reports Positive Initial Phase 1b Results For ALN-HTT02(RTTNews) – Alnylam Pharmaceuticals (ALNY) reported positive initial Phase 1b clinical trial results for ALN-HTT02, an investigational RNAi therapeutic in development for the treatment of Huntington's disease. ALN-HTT02 will be developed under the International Nonproprietary Nam
- Zacks · Oct 22, 9:00 AM EDTAlnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Alnylam Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.